Cantor Fitzgerald analyst Ross Osborn downgraded Asensus Surgical to Neutral from Overweight without a price target. The analyst cites liquidity and balance sheet concerns and the resultant lack of visibility to the company’s near-term financial performance for the downgrade. The firm believes Asensus will need $60M of capital next year, which is roughly the size of the company’s current market capitalization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASXC:
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2023
- Asensus Surgical Announces Sale of Senhance Robotic System
- Asensus Surgical sells Senhance Surgical System to distribution partner
- Asensus enters agreement with Flex for Luna Surgical System
- Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System
